Table 2.
Treatment-emergent toxicities
| Toxicities | 1 months after initial DEB-TACE 1 (n = 13)
|
||
|---|---|---|---|
| All grades | Grades 1–2 | Grades 3–4 | |
| Any (%) | 13 (100) | ||
| Blood/bone marrow suppression (%) | |||
| Anemia | 1 (8) | 1 (8) | |
| Lymphopenia | 2 (15) | 2 (15) | |
| Cardiac events | |||
| Hypotension | 1 (8) | 1 (8) | |
| Cardiovascular system (%) | |||
| Edema | 2 (15) | 2 (15) | |
| Coagulation (%) | |||
| Increased INR | 2 (15) | 2 (15) | |
| Constitutional symptoms (%) | |||
| Fatigue | 9 (69) | 6 (46) | 3 (23) |
| Fever | 4 (31) | 4 (31) | |
| Night sweats | 6 (46) | 6 (46) | |
| Dermatologic events (%) | |||
| Alopecia | 3 (23) | 3 (23) | |
| Dry skin | 1 (8) | 1 (8) | |
| Gastrointestinal events (%) | |||
| Ascites | 1 (8) | 1 (8) | |
| Anorexia | 5 (38) | 5 (38) | |
| Biloma | 5 (38) | 5 (38) | |
| Constipation | 1 (8) | 1 (8) | |
| Diarrhea | 1 (8) | 1 (8) | |
| Nausea | 1 (8) | 1 (8) | |
| Taste alteration | 1 (8) | 1 (8) | |
| Hemorrhage/bleeding (%) | |||
| Hematoma | 1 (8) | 1 (8) | |
| Hepatic function (%) | |||
| Increased ALT | 5 (38) | 3 (23) | 2 (15) |
| Increased AST | 6 (46) | 6 (46) | |
| Increased AP | 8 (62) | 8 (62) | |
| Hyperbilirubinemia | 1 (8) | 1 (8) | |
| Hypoalbuminemia | 5 (38) | 5 (38) | |
| Infection (%) | |||
| Liver abscess | 1 (15) | 1 (15) | |
| Metabolic (%) | |||
| Hyperglycemia | 5 (38) | 3 (23) | 2 (15) |
| Hyponatremia | 1 (8) | 1 (8) | |
| Neurologic symptoms/events (%) | |||
| Neuropathy | 1 (8) | 1 (8) | |
| Pain (%) | |||
| Abdominal nonspecific | 5 (38) | 4 (31) | 1 (8) |
| Right upper quadrant | 6 (46) | 6 (46) | |
| Other | 1 (8) | 1 (8) | |
| Pulmonary (%) | |||
| Dyspnea | 1 (8) | 1 (8) | |
| Dyspnea on exertion | 1 (8) | 1 (8) | |